Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.
Also called NCT07223892
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Sponsor
- Bardia Anvar
- Registry
-
NCT07223892
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07223892. Randomized; single masking; primary purpose treatment. Start 2026-01-01 (anticipated); primary completion 2028-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
- Condition
- Chronic Wounds
- Condition
- Venous Leg Ulcers (VLUs)
- Condition
- Diabetic Foot Ulcers (DFUs)
- Condition
- Arterial Ulcers
- Condition
- Pressure Ulcers
- Condition
- Burn Wounds
- Condition
- Trauma Wounds
- Condition
- Surgical Wounds
- Intervention (Biological)
- Amniotic Tissue Allograft
- Lead sponsor
- Bardia Anvar
- Collaborator
- Carbon Life Sciences
Record details
- Record id
cardio:ct-nct07223892- Content hash
8dcb1048383327e0d843d529e4fe787795aa6eac8d30f13e1d3a7db0c25943d8